← Oncology Approval Tracker

FDA DECISION ·

Opdivo Qvantig

nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb

FDA approvalNew or expanded indicationMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Expands subcutaneous use to patients age 12 years or older weighing at least 30 kg for unresectable or metastatic melanoma alone or after IV nivolumab plus ipilimumab, and after complete resection of stage IIB, IIC, III, or IV melanoma.

LAMPGEN ANALYSIS

Why it matters

The action adds a subcutaneous option for eligible adolescents across advanced and adjuvant melanoma settings.

What research teams should watch

Document staging, resection and any IV induction treatment, then select the correct schedule and duration.

PRIMARY RECORDS

Sources